PLASTIWARD™

Robust in-plastic security system for medical devices and pharmaceutical packaging

To fight the rise of counterfeit medicines and devices in the healthcare industry, Clariant and SICPA have jointly developed PLASTIWARD™, a complete in-plastic solution that effectively protects from counterfeiting and dilution, while enabling pharma and medical devices companies to guarantee supply chain integrity with low impact on productivity and operations. Our joint expertise in the management of security and polymer solutions allows us to be an ideal partner to design, deploy and monitor a tailor-made approach to answer your needs in terms of security and compliance.

Our mission is to help you fulfill your promise of access to safe medicines to millions of patients and consumers around the world.

What is PLASTIWARD™?

Customisable in-plastic security feature

PLASTIWARD™ is a customisable in-plastic security solution combining exclusive taggants integrated into masterbatches with a secure data platform. The solution integrates:

- a polymer compound or masterbatch concentrate available in a range of polymers and colors supporting regulatory requirements through USP and ISO declarations and production under ISO13485 cGMP;
- a proprietary, unique and invisible taggant exclusively reserved for security applications;
- a proprietary detection device providing instant and unbiased authentication. The combination of taggant and reader is virtually impossible to reverse engineer;
- a secure inspection platform developed for monitoring and tracking field auditing activities and processes.

Note: Clariant Medical Policy - Restrictions on applications apply.
Web: http://www.clariant.com/mevopur

CLARIANT MAKES NO REPRESENTATION, PROMISE, OR EXPRESS OR IMPLIED WARRANTY CONCERNING THE SUITABILITY OR LAWFULNESS FOR USE IN ANY MEDICAL DEVICE UNLESS EXPRESSLY STATED IN A WRITTEN AGREEMENT SIGNED BY A DULY AUTHORIZED CLARIANT REPRESENTATIVE.
PLASTIWARD™: ROBUST IN-PLASTIC SECURITY FOR

PHARMACEUTICAL PACKAGING AND MEDICAL DEVICES

The light and ergonomic detection device is calibrated to validate the unique taggant signal. Connected to the dedicated inspection platform via Bluetooth, it enables fast and reliable authentication.

End-to-end tailor-made solution for your specific needs

Thanks to our long-time expertise and combined R&D competences, we have developed PLASTIWARD™ as a complete end-to-end approach tailored to your value chain and comprising:

- complete evaluation and analysis of your needs;
- solution identification & design;
- global deployment, training, maintenance and after-sales;
- instant, real-time on-going monitoring system via secure data base management;
- integrated quality control;
- fully controlled supply chain;
- customisable service for both in-house and outsourced operations.

Note: Clariant Medical Policy - Restrictions on applications apply.
For more information please see individual product data sheet available on request.
Web: http://www.clariant.com/mevopur

CLARIANT PLASTICS & COATINGS LTD
BU Masterbatches
Rothausstrasse 61
4132 Muttenz
Switzerland
Healthcare Polymer Solutions

COPYRIGHT ©
CLARIANT INTERNATIONAL LTD 2016
ISSUE: Released V1 Sept2016

SICPA
Product & Brand Protection
Avenue de Florissant 41
1008 Prilly
Switzerland
www.sicpa.com
brandprotection@sicpa.com
© 2016 SICPA Holding SA, Switzerland

Clariant & SICPA solution approach supports connected
PLASTIWARD™: ROBUST IN-PLASTIC SECURITY FOR

PHARMACEUTICAL PACKAGING AND MEDICAL DEVICES

Security starts with production

The taggant is proprietary to SICPA, patented and produced in-house under ISO 9001. The complex manufacturing process and material science behind these synthesised taggants, as well as the engineering of the detection methodology are exclusively marketed, support a fully controlled and traceable supply chain.

The production of the masterbatch or compound using the taggant is carried out at Clariant under strict protocols established under ISO standard (EN:ISO13485 cGMP) for the medical and pharmaceutical industry. These protocols enable tight control and full traceability of raw materials. Hence the control and consistency of the product is maintained throughout the product lifecycle. Ingredients used in the masterbatch / compound are biologically evaluated using ISO10993-1 and USP chapters <87>,<88> and European Pharmacopoeia monograph 3.1 and USP <661.1> (physiochemical tests) (Results pending).

Combined expertise of two leading partners in their respected industries

- two-in-one: complementary know-how in polymers and product protection/security that are regulatory compliant with pharma industry
- innovation and authentication: opening new horizons for innovation in plastic design coupled with built-in fake-proof security
- enhanced patient and consumer safety resulting from combined R&D strengths

Note: Clariant Medical Policy - Restrictions on applications apply. For more information please see individual product data sheet available on request. Web: http://www.clariant.com/mevopur
A modular solution

Our solution has been designed to meet pharma standards, while taking into account the wide array of needs and structures of our pharma clients. The PLASTIWARD™ system and technology can be combined with other products and technologies from Clariant and SICPA to provide multi-level security features protecting the device, primary packaging and secondary packaging. Our design integration and technical teams are available to help you define the most suitable solution according to your needs.

This unique approach offers pharma companies major benefits

- **Seamless solution**
  - complete end-to-end innovation tailored to client’s value chain and needs;
  - reduced complexity of the supply chain with a two-in-one approach;
  - on-going monitoring of the product throughout its life-cycle;

- **Robust proven system**
  - state-of-the-art security, instant and unbiased authentication since it is plastic embedded;
  - virtually impossible to reproduce as it is based on exclusive, proprietary and patented solutions;
  - combination of in-house material and digital components;

- **Compliance with pharma processes**
  - low impact on direct production processes and costs;
  - availability as compound or masterbatch concentrate in a range of polymers typically used in medical and pharmaceutical devices eg PE, PP, ABS, PC etc.;
  - availability with Drug Master File (type III) DMF27630 and Device Masterfile (MAF) to latest FDA requirements